SCHEMBL15976372

SCHEMBL15976372

CCOC(=O)Cc1ccc(OC)c(B2Oc3ccccc3O2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.42
ALOX5 P09917 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
NPC1 O15118 1/20 0.41
PKM P14618 1/20 0.41
NFKB1 P19838 1/20 0.41
RAB9A P51151 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
GAA P10253 2/20 0.40
MAPT P10636 1/20 0.40
PPARG P37231 2/20 0.40
PPARA Q07869 2/20 0.40
ALDH1A1 P00352 2/20 0.40
RECQL P46063 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12901862 0.86 DRD2 (0.38) DRD2L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL137326 0.82 UCHL1 (0.47) DRD2L3MBTL1SMN1; SMN2GAAALDH1A1
SCHEMBL12222637 0.81 DRD2 (0.41) DRD2ALOX5L3MBTL1GAAALDH1A1
SCHEMBL15976369 0.79 DRD2 (0.41) DRD2L3MBTL1GAAMAPTALDH1A1
SCHEMBL908271 0.76 ABL1 (0.59) DRD2L3MBTL1NPC1SMN1; SMN2CYP1A2
SCHEMBL12191688 0.75 L3MBTL1 (0.50) DRD2L3MBTL1NPC1PKMNFKB1
SCHEMBL349587 0.74 GAA (0.67) NFKB1SMN1; SMN2CYP1A2CYP3A4GAA
SCHEMBL7886073 0.72 HTT (0.54) DRD2RAB9AALDH1A1ABL1RIN1
SCHEMBL134808 0.72 ABL1 (0.59) DRD2L3MBTL1SMN1; SMN2GAAALDH1A1
SCHEMBL3782064 0.72 LMNA (0.55) DRD2SMN1; SMN2CYP1A2CYP2C19GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9572785-B2 DP2 antagonist and uses thereof BRICKELL BIOTECH, INC. (US) 2017-02-21 US disclosed
US-20160136119-A1 DP2 ANTAGONIST AND USES THEREOF BRICKELL BIOTECH, INC. 2016-05-19 US disclosed
US-8815917-B2 DP2 antagonist and uses thereof PANMIRA PHARMACEUTICALS, LLC (US) 2014-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160136119-A1 DP2 ANTAGONIST AND USES THEREOF PTGER2, PTGES2, PTGDR2 DRD2 542/4885ALOX5 61/4885L3MBTL1 2883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.